10:00 IMMU Immunomedics reports targeted therapy for advanced pancreatic cancer improves survival (3.46 +0.10) Co announced that repeated therapy cycles of its proprietary antibody, clivatuzumab tetraxetan, labeled with yttrium-90 (Y-90) plus low-dose gemcitabine at 200 mg/m2, extended median overall survival (OS) to 11.8 months, more than double the 5.4 months OS in patients treated with a single cycle. Increased Y-90 doses also improved responses; patients receiving a dose of 12 mCi/m2 or
Share This Post:
My Enzo & 599GTB http://www.flickr.com/photos/30532649@N02/sets/72157613596261365/ | |
|